9 Result(s)
within
Vallerie V. McLaughlin
-
Article
Open AccessMacitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset
Data on real-world clinical practice and outcomes of patients with pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH) are scarce. The OPUS/OrPHeUS studies enrolled patients new...
-
Article
Open AccessSafety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies
Portopulmonary hypertension (PoPH) carries a worse prognosis than other forms of pulmonary arterial hypertension (PAH). Data regarding use of PAH-specific therapies in patients with PoPH are sparse as they are...
-
Article
Open AccessLong-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
In the event-driven GRIPHON randomised-controlled trial, the oral prostacyclin receptor agonist selexipag significantly reduced the risk of disease progression (composite primary endpoint of morbidity/mortalit...
-
Article
Open AccessClinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
Initial combination therapy with ambrisentan and tadalafil reduced the risk of clinical failure events for treatment-naïve participants with pulmonary arterial hypertension (PAH) as compared to monotherapy. Pr...
-
Article
Open AccessRiociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (E...
-
Article
Right atrial strain is predictive of clinical outcomes and invasive hemodynamic data in group 1 pulmonary arterial hypertension
Transthoracic echocardiography (TTE) is a practical and widely used tool for risk stratification in pulmonary arterial hypertension (PAH). We hypothesized that right atrial (RA) reservoir function, represented...
-
Article
Pulmonary Hypertension in Women: What Does the Cardiologist Need to Know?
Our goal is to review the epidemiology, diagnosis, and management of PH focusing on how this condition affects women.
-
Article
Open AccessBorderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study
Patients with mean pulmonary artery pressures (mPAP) of 21 to 24 mm Hg have a so-called borderline elevation of mPAP (BoPAP)—a condition thought to represent early-stage pulmonary arterial vasculopathy. Based ...
-
Reference Work Entry In depth
Pulmonary Hypertension
